Exchange: NASDAQ·Updated 07:30 PM EST

ONC News

News
all
press releases
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock Has Average Price Target of $441.64 According to Analysts
Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) have received an average rating of "Buy" from the eighteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, sixteen have issued a buy r...
MarketBeat
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock Has Average Price Target of $441.64 According to Analysts
Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) have received an average rating of "Buy" from the eighteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, sixteen have issued a buy r...
MarketBeat
More News
JPMorgan Chase & Co. increased their price objective on shares of BeOne Medicines from $445.00 to $460.00 and gave the stock an "overweight" rating in a research report on Thursday...
MarketBeat
BeOne Medicines (NASDAQ:ONC) has outperformed the market over the past 10 years by 16.62% on an annualized basis producing an average annual return of 29.37%. Currently, BeOne Medicines has a market capitalization ofread more...
Benzinga
Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Revolution Medicines' Q3 revenues beat estimates as Rasonque generated $197.6 million in just five weeks, signaling strong early launch demand.
Zacks
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: Our strong third quarter results and raised full-year guidance...
Business Wire
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA (zanubrutinib) in combination with...
Business Wire
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
Zacks
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed...
Business Wire
HPE, AER, UGP, ONC and BWFG have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2026.
Zacks

Advertisement|Remove ads.